Monthly Communication Report

Corporation:	Gilead Sciences Canada
Associated registration:	959600-360912-16
Communication date:	2025-10-23
Posted date:	2025-11-15

Designated Public Office Holders who participated in the communication:	David McFarlane, Director of Policy Minister of Industry and Minister Responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
List of Details Subject matter Detail Health, Science and Technology Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines. Economic Development, Employment and Training, Health, Industry, Intellectual Property, Research and Development, Science and Technology Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Responsible Officer who filed this communication report:	Paul Petrelli
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.